POST-PRESENTATION SURVEY
Thank you for participating in our presentation.
Q1
I am a(n)...
MD/DO
NP
PA
Other
MD/DO
NP
PA
Other
Q2
If you selected "Other," please provide:
Q3
How many years have you been in practice?
1-5
6-10
11-15
16-20
Over 20
1-5
6-10
11-15
16-20
Over 20
Q4
Number of patients do you see per month with...?
1-10
11-20
21-30
31-40
41-50
Over 50
T2DM
T2DM 1-10
T2DM 11-20
T2DM 21-30
T2DM 31-40
T2DM 41-50
T2DM Over 50
DKD
DKD 1-10
DKD 11-20
DKD 21-30
DKD 31-40
DKD 41-50
DKD Over 50
Q5
Please describe your practice setting:
Solo Practice
Group Practice
Hospital Setting
Clinic
Other
Solo Practice
Group Practice
Hospital Setting
Clinic
Other
Q6
If you selected "Other," please describe
Q7
Please rate the following:
Unsatisfactory
Needs Improvement
Average
Above Average
Excellent
Degree to which educational expectations were met
Degree to which educational expectations were met Unsatisfactory
Degree to which educational expectations were met Needs Improvement
Degree to which educational expectations were met Average
Degree to which educational expectations were met Above Average
Degree to which educational expectations were met Excellent
Material was relevant to my practice
Material was relevant to my practice Unsatisfactory
Material was relevant to my practice Needs Improvement
Material was relevant to my practice Average
Material was relevant to my practice Above Average
Material was relevant to my practice Excellent
Effective Faculty Presenter
Effective Faculty Presenter Unsatisfactory
Effective Faculty Presenter Needs Improvement
Effective Faculty Presenter Average
Effective Faculty Presenter Above Average
Effective Faculty Presenter Excellent
Overall Program
Overall Program Unsatisfactory
Overall Program Needs Improvement
Overall Program Average
Overall Program Above Average
Overall Program Excellent
Q8
Please rate your ability to achieve the Learning Objectives below:
Not at all
Somewhat
Mostly
Completely
Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2DM)
Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2DM) Not at all
Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2DM) Somewhat
Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2DM) Mostly
Identify the risks of kidney disease and their consequences in patients with type 2 diabetes (T2DM) Completely
Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2DM
Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2DM Not at all
Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2DM Somewhat
Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2DM Mostly
Appropriately screen for the presence of chronic kidney disease (CKD) in patients with T2DM Completely
Initiate evidence-based therapy to slow the progression of kidney disease inpatients with T2DM and CKD
Initiate evidence-based therapy to slow the progression of kidney disease inpatients with T2DM and CKD Not at all
Initiate evidence-based therapy to slow the progression of kidney disease inpatients with T2DM and CKD Somewhat
Initiate evidence-based therapy to slow the progression of kidney disease inpatients with T2DM and CKD Mostly
Initiate evidence-based therapy to slow the progression of kidney disease inpatients with T2DM and CKD Completely
Become familiar with the mineralocorticoid receptor antagonist (MRA) and its role in treatment of patients with diabetic kidney disease (DKD).
Become familiar with the mineralocorticoid receptor antagonist (MRA) and its role in treatment of patients with diabetic kidney disease (DKD). Not at all
Become familiar with the mineralocorticoid receptor antagonist (MRA) and its role in treatment of patients with diabetic kidney disease (DKD). Somewhat
Become familiar with the mineralocorticoid receptor antagonist (MRA) and its role in treatment of patients with diabetic kidney disease (DKD). Mostly
Become familiar with the mineralocorticoid receptor antagonist (MRA) and its role in treatment of patients with diabetic kidney disease (DKD). Completely
Q9
Will you change your practice behaviors as a result of this presentation?
No
Unlikely
No Opinion
Probably
Absolutely
No
Unlikely
No Opinion
Probably
Absolutely
Q10
What will you change? Select as many of the following as you deem appropriate.
Change the medications I prescribe
More and better screening
Educate my patients
Know better when to refer
Educate my colleagues/staff
Adhere to the 2022 ADA guidelines
Other
Q11
Which medications are you now more likely to prescribe? You may select one, both, or neither.
MRAs
SGLT-2 inhibitors
Q12
If you selected "other," please tell us what you will change.
Q13
Because you have indicated that you may change your practice behaviors, you may be eligible for receive 2.0 credits for "Translation to Practice." Provide your email address below and you will be sent a special follow up survey in six weeks. If you have made changes to your practice behaviors, you will be issued your T2P certificate.
Q14
What barriers do you see to change?
Cost
Insurance Coverage
Formulry
Time with patient
Patient adherence
Other
Cost
Insurance Coverage
Formulry
Time with patient
Patient adherence
Other
Q15
If you selected "other," please tell us what other barriers you expect.
Q16
Did the content contribute valuable information that will assist in improving patient outcomes?
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
Q17
What was your level of expertise on this topic?
None
Little
Some
Considerable
Extensive
Before
this presentation
Before
this presentation
None
Before
this presentation
Little
Before
this presentation
Some
Before
this presentation
Considerable
Before
this presentation
Extensive
AFTER
this presentation
AFTER
this presentation
None
AFTER
this presentation
Little
AFTER
this presentation
Some
AFTER
this presentation
Considerable
AFTER
this presentation
Extensive
Q18
Do you believe the activity was fair and balanced, free from commercial influences?
Yes
No
Yes
No
Q19
Did the program increase your competence?
Yes
No
Yes
No
Q20
According to the 2022 ADA Standards of Medical Care in Diabetes, for which group of patients with diabetes and CKD is finerenone recommended?
A. In patients who are at increased CV risk, upon diagnosis of CKD
B. In patients who are at increased CV risk, upon progression to stage 3 CKD.
C. In patients who are at increased CV risk or are unable to use an SGLT2 inhibitor
D. In patients who are at increased CV risk and are unable to tolerate ACE inhibitor, ARB, or SGLT2 therapy
Q21
Which of the following is a benefit of non-steroidal mineralocorticoid receptor antagonists (MRAs) but not of steroidal MRAs?
A. Reduction in albuminuria
B. Lower risk of hyperkalemia
C. Slowed progression of kidney disease
D. Cardiovascular benefits
Q22
How confident do you feel in your answer to the previous question?
Not at all confident
Somewhat confident
Confident
Very confident
..
.. Not at all confident
.. Somewhat confident
.. Confident
.. Very confident
Q23
Any additional comments?